Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Regulation of ROS in myeloid-derived suppressor cells through targeting fatty-acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy

(2021) Adeleye Oluwatosin Adeshakin et al.   CELLULAR IMMUNOLOGY

Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment

(2021) Xian-Ning Wu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

(2021) Xingzhe Ma et al.   Cell Metabolism

CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours

(2021) Roberta Zappasodi et al.   NATURE

Lipid signalling enforces functional specialization of Treg cells in tumours

(2021) Seon Ah Lim et al.   NATURE

Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes

(2021) Li Jia et al.   BIOMATERIALS

Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization

(2021) Nian Liu et al.   MOLECULAR THERAPY

Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy

(2021) Anne Montfort et al.   Cancer Immunology Research

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck

(2021) Dan P Zandberg et al.   Journal for ImmunoTherapy of Cancer

Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors

(2021) Shihao Xu et al.   IMMUNITY

Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes

(2021) Mikako Nishida et al.   Journal for ImmunoTherapy of Cancer

Regulatory T Cell Development

(2020) Peter A. Savage et al.   Annual Review of Immunology

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1

(2020) Caroline Imbert et al.   Nature Communications

Methionine Restriction and Cancer Biology

(2020) Desiree Wanders et al.   Nutrients

Fatty acid oxidation controls CD8+ tissue-resident memory T cell survival in gastric adenocarcinoma

(2020) Run Lin et al.   Cancer Immunology Research

Molecular mechanism of SHP2 activation by PD-1 stimulation

(2020) M. Marasco et al.   Science Advances

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

(2020) Laura Strauss et al.   Science Immunology

Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer

(2020) Biagio Ricciuti et al.   CLINICAL CANCER RESEARCH

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

(2020) Hiro Sato et al.   International Journal of Clinical Oncology

IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism

(2020) Atsuhito Tsuji et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer

(2020) Ying Z. Mazzu et al.   Molecular Oncology

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

(2020) Anniina Färkkilä et al.   Nature Communications

Replication Stress, DNA Damage, Inflammatory Cytokines and Innate Immune Response

(2020) Sandrine Ragu et al.   Genes

Methionine Dependence of Cancer

(2020) Peter Kaiser   Biomolecules

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

(2020) Yunpeng Yang et al.   Journal of Thoracic Oncology

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression

(2020) Nan-Nan Zheng et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy

(2020) Luana Guerra et al.   Cell Reports

Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity

(2020) Dawei Chen et al.   Journal for ImmunoTherapy of Cancer

Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer

(2020) Jason R Brown et al.   JCI Insight

Overcoming acquired resistance to PD-1 inhibitor with the addition of metformin in small cell lung cancer (SCLC)

(2020) Yeseul Kim et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways

(2020) Alexandra Giatromanolaki et al.   LIFE SCIENCES

Cancer SLC43A2 alters T cell methionine metabolism and histone methylation

(2020) Yingjie Bian et al.   NATURE

Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma

(2020) Ali Mehdi et al.   Frontiers in Oncology

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

(2020) Yue Gong et al.   Cell Metabolism

Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment

(2019) Zehang Jiang et al.   EBioMedicine

HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate Biosynthesis

(2019) Florinda Meléndez-Rodríguez et al.   Cell Reports

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

(2019) Triparna Sen et al.   Cancer Discovery

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

(2019) Michael Platten et al.   NATURE REVIEWS DRUG DISCOVERY

Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance

(2019) Peter Kim Moon et al.   Journal of Translational Medicine

Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment

(2019) Xingzhe Ma et al.   Cell Metabolism

PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy

(2019) Xinyi Tu et al.   MOLECULAR CELL

Nanoenabled Modulation of Acidic Tumor Microenvironment Reverses Anergy of Infiltrating T Cells and Potentiates Anti-PD-1 Therapy

(2019) Yu-Xue Zhang et al.   NANO LETTERS

Epstein-Barr-Virus-Induced One-Carbon Metabolism Drives B Cell Transformation

(2019) Liang Wei Wang et al.   Cell Metabolism

Acetylation regulates ribonucleotide reductase activity and cancer cell growth

(2019) Guo Chen et al.   Nature Communications

Akt and STAT5 mediate naïve human CD4+ T-cell early metabolic response to TCR stimulation

(2019) Nicholas Jones et al.   Nature Communications

The Metabolic Signature of Macrophage Responses

(2019) Antonella Viola et al.   Frontiers in Immunology

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

(2019) Panagiotis A. Konstantinopoulos et al.   JAMA Oncology

PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes

(2019) Jesús Ogando et al.   Journal for ImmunoTherapy of Cancer

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

(2019) Andrea Forschner et al.   Journal for ImmunoTherapy of Cancer

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence

(2019) Michal Harel et al.   CELL

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

(2019) Michael Friedlander et al.   LANCET ONCOLOGY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade

(2019) Gang Xue et al.   Frontiers in Genetics

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses

(2019) Xi Chen et al.   Acta Pharmaceutica Sinica B

STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth

(2019) Chunyan Zhang et al.   Cell Metabolism

Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer

(2019) Guofeng Ma et al.   MOLECULAR CANCER RESEARCH

Metabolic Consequences of T-cell Costimulation in Anticancer Immunity

(2019) Alvaro Teijeira et al.   Cancer Immunology Research

Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis

(2019) Nicolaos Jay Palaskas et al.   Cell Discovery

Dysregulation of glutaminase and glutamine synthetase in cancer

(2019) José M. Matés et al.   CANCER LETTERS

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Targeting tumor-associated acidity in cancer immunotherapy

(2018) Ruben Lacroix et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Checkpoint inhibitors in breast cancer – Current status

(2018) Anne Polk et al.   CANCER TREATMENT REVIEWS

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

(2018) Min Yuen Teo et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety of combining radiotherapy with immune-checkpoint inhibition

(2018) William L. Hwang et al.   Nature Reviews Clinical Oncology

Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences

(2018) Diwakar Davar et al.   Targeted Oncology

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation

(2018) Alvaro Teijeira et al.   Cancer Immunology Research

mTOR at the Transmitting and Receiving Ends in Tumor Immunity

(2018) Yakir Guri et al.   Frontiers in Immunology

Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy

(2018) Soumaya Kouidhi et al.   Frontiers in Immunology

The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy

(2018) Lilla Hornyák et al.   Frontiers in Immunology

Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy

(2018) Yiliang Li et al.   Frontiers in Immunology

pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma

(2018) Olga Kuchuk et al.   OncoImmunology

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma

(2018) Muhammad Zubair Afzal et al.   Journal for ImmunoTherapy of Cancer

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy

(2018) Preeti Kanikarla-Marie et al.   Frontiers in Oncology

Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy

(2018) Sun-Hee Kim et al.   Frontiers in Oncology

Glutaminase isoenzymes in the metabolic therapy of cancer

(2018) José M. Matés et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors

(2018) Toshio Kubo et al.   Clinical Lung Cancer

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

GITR Agonism Enhances Cellular Metabolism to Support CD8+ T-cell Proliferation and Effector Cytokine Production in a Mouse Tumor Model

(2018) Simran S. Sabharwal et al.   Cancer Immunology Research

Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model

(2018) Mayu Tomita et al.   EJNMMI Research

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

(2018) Thibault Le Bourgeois et al.   Frontiers in Oncology

Reinforce the antitumor activity of CD8+ T cells via glutamine restriction

(2018) Shogo Nabe et al.   CANCER SCIENCE

Novel insights into molecular chaperone regulation of ribonucleotide reductase

(2018) Laura E. Knighton et al.   CURRENT GENETICS

Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion

(2018) Qiang Fu et al.   EUROPEAN UROLOGY

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

(2018) Xin Jin et al.   MOLECULAR CELL

Defective respiration and one-carbon metabolism contribute to impaired naïve T cell activation in aged mice

(2018) Noga Ron-Harel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Energy metabolism drives myeloid-derived suppressor cell differentiation and functions in pathology

(2017) Antonio Sica et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells

(2017) J Feng et al.   ONCOGENE

Metabolic control of regulatory T cell (Treg) survival and function by Lkb1

(2017) Nanhai He et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation

(2017) Veronica Huber et al.   SEMINARS IN CANCER BIOLOGY

PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration

(2017) Elena Brin et al.   Oncotarget

Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling

(2017) Isobel Okoye et al.   Oncotarget

Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy

(2017) Alison Taylor et al.   Frontiers in Immunology

Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors

(2017) Eva M. Palsson-McDermott et al.   Frontiers in Immunology

CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer

(2017) Jieyao Li et al.   OncoImmunology

Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma

(2016) H. Hirata et al.   CANCER RESEARCH

Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia

(2016) David B. Sykes et al.   CELL

Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin

(2016) Dan Y. Gui et al.   Cell Metabolism

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

(2016) Nicole E. Scharping et al.   IMMUNITY

Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses

(2016) Alison Taylor et al.   IMMUNITY

Tim-3 identifies exhausted follicular helper T cells in breast cancer patients

(2016) Shiguang Zhu et al.   IMMUNOBIOLOGY

Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression

(2016) Zhenxin Wang et al.   IMMUNOLOGICAL INVESTIGATIONS

Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia

(2016) Peter J. Siska et al.   JOURNAL OF IMMUNOLOGY

TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention

(2016) Karsten Mahnke et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Erratum

(2016)   JNCI-Journal of the National Cancer Institute

The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia

(2016) M Qorraj et al.   LEUKEMIA

NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis

(2016) Chi Ma et al.   NATURE

Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism

(2016) Wei Yang et al.   NATURE

Hypoxia inducible factor-1 mediates the expression of the immune checkpoint HLA-G in glioma cells through hypoxia response element located in exon 2

(2016) Layale Yaghi et al.   Oncotarget

Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer

(2016) Li Ren et al.   Oncotarget

Erratum

(2016)   JNCI-Journal of the National Cancer Institute

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

(2016) E. Moore et al.   Cancer Immunology Research

Hypoxia and antitumor CD8+ T cells: An incompatible alliance?

(2016) Romain Vuillefroy de Silly et al.   OncoImmunology

Hepatocellular carcinoma is accelerated by NASH involving M2 macrophage polarization mediated by hif-1αinduced IL-10

(2016) Aditya Ambade et al.   OncoImmunology

Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20)

(2016) Natalie Burrows et al.   Scientific Reports

MHC class II association with lipid rafts on the antigen presenting cell surface

(2015) Howard A. Anderson et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy

(2015) Shari Pilon-Thomas et al.   CANCER RESEARCH

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses

(2015) Ping-Chih Ho et al.   CELL

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Lactate promotes glutamine uptake and metabolism in oxidative cancer cells

(2015) Jhudit Pérez-Escuredo et al.   CELL CYCLE

Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages

(2015) Eva M. Palsson-McDermott et al.   Cell Metabolism

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

(2015) Zhaoyong Li et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4

(2015) L. Liu et al.   CLINICAL CANCER RESEARCH

Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications

(2015) Rebecca Kohnken et al.   Molecular Cancer

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

(2015) Huimin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation

(2015) Dorota Klysz et al.   Science Signaling

Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells

(2015) Rei Watanabe et al.   Science Translational Medicine

T cell metabolic fitness in antitumor immunity

(2015) Peter J. Siska et al.   TRENDS IN IMMUNOLOGY

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation

(2015) Dorota Klysz et al.   Science Signaling

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

(2015) Paul A. Beavis et al.   Cancer Immunology Research

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

(2015) M. D. Sharma et al.   Science Advances

Hypoxia and cancer cell metabolism

(2014) D. Huang et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Tissue-Resident Memory T Cells

(2014) Jason M. Schenkel et al.   IMMUNITY

Memory CD8+ T Cells Use Cell-Intrinsic Lipolysis to Support the Metabolic Programming Necessary for Development

(2014) David O’Sullivan et al.   IMMUNITY

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Fructose-1,6-bisphosphatase opposes renal carcinoma progression

(2014) Bo Li et al.   NATURE

Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function

(2014) Andrea Viale et al.   NATURE

Mitigating the toxic effects of anticancer immunotherapy

(2014) Tara C. Gangadhar et al.   Nature Reviews Clinical Oncology

Metabolic reprogramming during TGFβ1-induced epithelial-to-mesenchymal transition

(2014) L Jiang et al.   ONCOGENE

Increased CD112 Expression in Methylcholanthrene-Induced Tumors in CD155-Deficient Mice

(2014) Yoko Nagumo et al.   PLoS One

Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges

(2014) Melissa M. Phillips et al.   Cancer Research and Treatment

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

Glutamine and cancer: cell biology, physiology, and clinical opportunities

(2013) Christopher T. Hensley et al.   JOURNAL OF CLINICAL INVESTIGATION

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway

(2013) Jaekyoung Son et al.   NATURE

Toll-Like Receptor Ligands Induce Expression of the Costimulatory Molecule CD155 on Antigen-Presenting Cells

(2013) Neha Kamran et al.   PLoS One

Prognostic significance of CD155 mRNA expression in soft tissue sarcomas

(2013) SATORU ATSUMI et al.   Oncology Letters

Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence

(2013) Katherine M. Aird et al.   Cell Reports

pH sensing and regulation in cancer

(2013) Mehdi Damaghi et al.   Frontiers in Physiology

Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses

(2012) Nathanael J. Spann et al.   CELL

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

(2012) Hang Li et al.   HEPATOLOGY

Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation

(2012) A. Gupta et al.   JOURNAL OF IMMUNOLOGY

Purinergic Signaling during Inflammation

(2012) Holger K. Eltzschig et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1

(2011) Weibo Luo et al.   CELL

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality

(2011) D. A. Chan et al.   Science Translational Medicine

Interferon-  and tumor necrosis factor-  induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes

(2010) A. Kondo et al.   BLOOD

Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma

(2010) Reiko Nakai et al.   CANCER SCIENCE

HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment

(2010) Cesar A. Corzo et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Oxidative Phosphorylation Induces De Novo Expression of the MHC Class I in Tumor Cells through the ERK5 Pathway

(2010) S. Charni et al.   JOURNAL OF IMMUNOLOGY

Lipid accumulation and dendritic cell dysfunction in cancer

(2010) Donna L Herber et al.   NATURE MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glutamine addiction: a new therapeutic target in cancer

(2010) David R. Wise et al.   TRENDS IN BIOCHEMICAL SCIENCES

Structure-Function analysis of the CTLA-4 interaction with PP2A

(2009) Wendy A Teft et al.   BMC IMMUNOLOGY

Tumor-Infiltrating Regulatory Dendritic Cells Inhibit CD8+ T Cell Function via L-Arginine Metabolism

(2009) L. A. Norian et al.   CANCER RESEARCH

Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine

(2009) M. K. Srivastava et al.   CANCER RESEARCH

Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus

(2009) Thomas Gebhardt et al.   NATURE IMMUNOLOGY

TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells

(2008) Yigang Qian et al.   CANCER INVESTIGATION

LXR Signaling Couples Sterol Metabolism to Proliferation in the Acquired Immune Response

(2008) Steven J. Bensinger et al.   CELL

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

(2008) Xin Yu et al.   NATURE IMMUNOLOGY